FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096829102> ?p ?o ?g. }

• W2096829102 endingPage "293" @default.
• W2096829102 startingPage "287" @default.
• W2096829102 abstract "Summary Rivaroxaban, the first direct factor-Xa inhibitor anticoagulant, has been approved for the prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery, for stroke prophylaxis in patients with non-valvular atrial fibrillation and for the treatment of deep vein thrombosis. There is no requirement for coagulation monitoring with rivaroxaban in routine clinical practice. However, in certain clinical circumstances such as life-threatening bleeding or an emergency operation the measurement of the thromboplastin time with a sensitive reagent will deliver first information. A quantitative determination of rivaroxaban plasma concentration is possible using an anti-factor Xa assay. In the case of a patient under long-term anticoagulation with rivaroxaban requiring an elective surgery, a discontinuation of rivaroxaban 20 to 30 hours before the operation is sufficient to normalize the associated bleeding risk, as long as the renal and liver function is normal. A longer interval should be taken into consideration, when the patient presents a renal and liver impairment or is of a higher age. In the event of an emergency operation effective rivaroxaban concentrations might be present. Nevertheless, we advise against using a prophylactic dose of factor concentrates. Recommendations: From a clinical perspective, in the event of a minor bleeding we recommend a temporary discontinuation of rivaroxaban, whereas for clinically relevant major or severe bleeding events a mechanical compression or a limited surgical i. e. interventional treatment is required. Supportive measures such as the administration of blood products or tranexamic acid might be beneficial. In addition to haemodynamic supportive measures life threatening bleeding events demand a comprehensive haemostasis management, as well as the application of PCC." @default.
• W2096829102 created "2016-06-24" @default.
• W2096829102 creator A5001586855 @default.
• W2096829102 creator A5003592595 @default.
• W2096829102 creator A5004003194 @default.
• W2096829102 creator A5018946153 @default.
• W2096829102 creator A5028142204 @default.
• W2096829102 creator A5053161165 @default.
• W2096829102 creator A5083911927 @default.
• W2096829102 creator A5086134082 @default.
• W2096829102 date "2012-01-01" @default.
• W2096829102 modified "2023-10-06" @default.
• W2096829102 title "Blutungsrisiko und Blutungsnotfälle unter Rivaroxaban" @default.
• W2096829102 cites W1839975480 @default.
• W2096829102 cites W1940756716 @default.
• W2096829102 cites W1975757685 @default.
• W2096829102 cites W1982825827 @default.
• W2096829102 cites W1989930316 @default.
• W2096829102 cites W1990249837 @default.
• W2096829102 cites W2019960723 @default.
• W2096829102 cites W2028162842 @default.
• W2096829102 cites W2036007875 @default.
• W2096829102 cites W2045987573 @default.
• W2096829102 cites W2053361486 @default.
• W2096829102 cites W2083713858 @default.
• W2096829102 cites W2097854437 @default.
• W2096829102 cites W2113446992 @default.
• W2096829102 cites W2115787552 @default.
• W2096829102 cites W2116930113 @default.
• W2096829102 cites W2117677020 @default.
• W2096829102 cites W2127090290 @default.
• W2096829102 cites W2130199362 @default.
• W2096829102 cites W2153438515 @default.
• W2096829102 cites W2167182965 @default.
• W2096829102 cites W2324437595 @default.
• W2096829102 doi "https://doi.org/10.5482/ha-2012030001" @default.
• W2096829102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23114797" @default.
• W2096829102 hasPublicationYear "2012" @default.
• W2096829102 type Work @default.
• W2096829102 sameAs 2096829102 @default.
• W2096829102 citedByCount "32" @default.
• W2096829102 countsByYear W20968291022013 @default.
• W2096829102 countsByYear W20968291022014 @default.
• W2096829102 countsByYear W20968291022015 @default.
• W2096829102 countsByYear W20968291022016 @default.
• W2096829102 countsByYear W20968291022017 @default.
• W2096829102 countsByYear W20968291022018 @default.
• W2096829102 countsByYear W20968291022021 @default.
• W2096829102 crossrefType "journal-article" @default.
• W2096829102 hasAuthorship W2096829102A5001586855 @default.
• W2096829102 hasAuthorship W2096829102A5003592595 @default.
• W2096829102 hasAuthorship W2096829102A5004003194 @default.
• W2096829102 hasAuthorship W2096829102A5018946153 @default.
• W2096829102 hasAuthorship W2096829102A5028142204 @default.
• W2096829102 hasAuthorship W2096829102A5053161165 @default.
• W2096829102 hasAuthorship W2096829102A5083911927 @default.
• W2096829102 hasAuthorship W2096829102A5086134082 @default.
• W2096829102 hasConcept C126322002 @default.
• W2096829102 hasConcept C141071460 @default.
• W2096829102 hasConcept C2776301958 @default.
• W2096829102 hasConcept C2778205648 @default.
• W2096829102 hasConcept C2778661090 @default.
• W2096829102 hasConcept C2778715236 @default.
• W2096829102 hasConcept C2779161974 @default.
• W2096829102 hasConcept C2779637338 @default.
• W2096829102 hasConcept C2780434524 @default.
• W2096829102 hasConcept C2780868729 @default.
• W2096829102 hasConcept C2991743468 @default.
• W2096829102 hasConcept C42219234 @default.
• W2096829102 hasConcept C71924100 @default.
• W2096829102 hasConceptScore W2096829102C126322002 @default.
• W2096829102 hasConceptScore W2096829102C141071460 @default.
• W2096829102 hasConceptScore W2096829102C2776301958 @default.
• W2096829102 hasConceptScore W2096829102C2778205648 @default.
• W2096829102 hasConceptScore W2096829102C2778661090 @default.
• W2096829102 hasConceptScore W2096829102C2778715236 @default.
• W2096829102 hasConceptScore W2096829102C2779161974 @default.
• W2096829102 hasConceptScore W2096829102C2779637338 @default.
• W2096829102 hasConceptScore W2096829102C2780434524 @default.
• W2096829102 hasConceptScore W2096829102C2780868729 @default.
• W2096829102 hasConceptScore W2096829102C2991743468 @default.
• W2096829102 hasConceptScore W2096829102C42219234 @default.
• W2096829102 hasConceptScore W2096829102C71924100 @default.
• W2096829102 hasIssue "04" @default.
• W2096829102 hasLocation W20968291021 @default.
• W2096829102 hasLocation W20968291022 @default.
• W2096829102 hasOpenAccess W2096829102 @default.
• W2096829102 hasPrimaryLocation W20968291021 @default.
• W2096829102 hasRelatedWork W1977378072 @default.
• W2096829102 hasRelatedWork W2060633440 @default.
• W2096829102 hasRelatedWork W2082905468 @default.
• W2096829102 hasRelatedWork W2336961616 @default.
• W2096829102 hasRelatedWork W2595529847 @default.
• W2096829102 hasRelatedWork W2600929608 @default.
• W2096829102 hasRelatedWork W2807517899 @default.
• W2096829102 hasRelatedWork W2896340756 @default.
• W2096829102 hasRelatedWork W2919772138 @default.
• W2096829102 hasRelatedWork W4206579814 @default.

• next